A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Inclusion Criteria: - Type 2 diabetes - Age above or equal to 50 years with predefinedprevious cardiovascular disease(s) or renal disease or age above or equal to 60 years withpredefined cardiovascular risk factors - HbA1c (glycosylated haemoglobin) above or equal to 7.0% or HbA1c below 7.0% and current insulin treatment corresponding to above or equal to 20 U of basal insulin per day - One or more oral or injectable antidiabetic agent(s)

Exclusion Criteria: - An acute coronary or cerebrovascular event in the previous 60 days -Planned coronary, carotid or peripheral artery revascularisation - Chronic heart failureNYHA (New York Heart Association) class IV - Current or past (within the last 5 years)malignant neoplasms (except basal cell and squamous cell skin carcinoma)